CRISPR Therapeutics AG (CRSP): Price and Financial Metrics

CRISPR Therapeutics AG (CRSP): $54.01

1.68 (+3.21%)

POWR Rating

Component Grades













Add CRSP to Watchlist
Sign Up

Industry: Biotech



in industry


  • CRSP scores best on the Growth dimension, with a Growth rank ahead of 31.18% of US stocks.
  • CRSP's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • CRSP ranks lowest in Stability; there it ranks in the 11th percentile.

CRSP Stock Summary

  • Of note is the ratio of CRISPR THERAPEUTICS AG's sales and general administrative expense to its total operating expenses; just 5.7% of US stocks have a lower such ratio.
  • With a price/sales ratio of 283.48, CRISPR THERAPEUTICS AG has a higher such ratio than 98.63% of stocks in our set.
  • Revenue growth over the past 12 months for CRISPR THERAPEUTICS AG comes in at -98.44%, a number that bests merely 0.75% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are XBIT, PTGX, RNA, NRIX, and NTLA.
  • Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to

CRSP Valuation Summary

  • CRSP's price/earnings ratio is -5.7; this is 125.79% lower than that of the median Healthcare stock.
  • Over the past 76 months, CRSP's price/sales ratio has gone down 91.4.

Below are key valuation metrics over time for CRSP.

Stock Date P/S P/B P/E EV/EBIT
CRSP 2023-01-30 277.6 2.0 -5.7 -5.4
CRSP 2023-01-27 293.3 2.1 -6.1 -5.7
CRSP 2023-01-26 280.4 2.0 -5.8 -5.5
CRSP 2023-01-25 282.0 2.0 -5.8 -5.5
CRSP 2023-01-24 288.7 2.1 -6.0 -5.6
CRSP 2023-01-23 285.2 2.1 -5.9 -5.6

CRSP Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 179.43%.
  • Its 5 year net cashflow from operations growth rate is now at 187.22%.
  • Its 5 year cash and equivalents growth rate is now at 180.78%.
Over the past 33 months, CRSP's revenue has gone down $275,499,000.

The table below shows CRSP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 14.091 -468.451 -680.848
2022-06-30 14.821 -444.562 -633.452
2022-03-31 915.364 504.396 311.607
2021-12-31 914.963 538.972 377.661
2021-09-30 902.434 543.798 411.87
2021-06-30 901.758 549.427 446.584

CRSP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRSP has a Quality Grade of C, ranking ahead of 73.06% of graded US stocks.
  • CRSP's asset turnover comes in at 0.441 -- ranking 101st of 681 Pharmaceutical Products stocks.
  • CDTX, NVS, and SEEL are the stocks whose asset turnover ratios are most correlated with CRSP.

The table below shows CRSP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.441 1 0.579
2021-03-31 0.001 1 -0.839
2020-12-31 0.001 1 -1.179
2020-09-30 0.067 1 -1.230
2020-06-30 0.301 1 0.242
2020-03-31 0.352 1 0.539

CRSP Price Target

For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $162.94 Average Broker Recommendation 1.55 (Moderate Buy)

CRSP Stock Price Chart Interactive Chart >

Price chart for CRSP

CRSP Price/Volume Stats

Current price $54.01 52-week high $86.95
Prev. close $52.33 52-week low $38.94
Day low $53.34 Volume 145,202
Day high $54.80 Avg. volume 1,007,900
50-day MA $49.24 Dividend yield N/A
200-day MA $60.02 Market Cap 4.23B

CRISPR Therapeutics AG (CRSP) Company Bio

CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.

CRSP Latest News Stream

Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream

Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

7 CRISPR Stocks With the Best Long-Term Potential 

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Alex Sirois on InvestorPlace | January 31, 2023

3 Gene Editing Stocks With the Best Long-Term Potential

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Muslim Farooque on InvestorPlace | January 25, 2023

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

Even in a risk-off market, gene editing stocks look attractive.

Chris Markoch on InvestorPlace | January 25, 2023

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.96, moving +1.25% from the previous trading session.

Yahoo | January 24, 2023

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

The Motley Fool | January 22, 2023

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo 31.73%
3-mo 5.53%
6-mo -33.65%
1-year -13.06%
3-year 2.47%
5-year 46.33%
YTD 32.87%
2022 -46.36%
2021 -50.51%
2020 151.39%
2019 113.18%
2018 21.68%

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9346 seconds.